The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)  

Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC  

Endorsed by the European Stroke Organisation (ESO)

/pdf/2016-esc-guidelines-for-the-management-of-atrial-ba0601yb9m.pdf

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

/pdf/2016-esc-guidelines-for-the-management-of-atrial-36b2cidm1x.pdf

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)

ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS

https://repub.eur.nl/pub/104203/REPUB_104203-OA.pdf

2017 HRS / EHRA / ECAS / APHRS / SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation

Authors/Task Force Members: Paulus Kirchhof* (Chairperson) (UK/Germany) Stefano Benussi* (Co-Chairperson) (Switzerland), Dipak Kotecha (UK), Anders Ahlsson (Sweden), Dan Atar (Norway), Barbara Casadei (UK), Manuel Castella (Spain), Hans-Christoph Diener (Germany), Hein Heidbuchel (Belgium), Jeroen Hendriks (The Netherlands), Gerhard Hindricks (Germany), Antonis S. Manolis (Greece), Jonas Oldgren (Sweden), Bogdan Alexandru Popescu (Romania), Ulrich Schotten (The Netherlands), Bart Van Putte (The Netherlands), and Panagiotis Vardas (Greece)

/pdf/2016-esc-guidelines-for-the-management-of-atrial-e0lfp612oq.pdf

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO)

Background—Specific noninvasive signal processing was applied to identify drivers in distinct categories of persistent atrial fibrillation (AF). Methods and Results—In 103 consecutive patients with persistent AF, accurate biatrial geometry relative to an array of 252 body surface electrodes was obtained from a noncontrast computed tomography scan. The reconstructed unipolar AF electrograms acquired at bedside from multiple windows (duration, 9±1 s) were signal processed to identify the drivers (focal or reentrant activity) and their cumulative density map. The driver domains were catheter ablated by using AF termination as the procedural end point in comparison with the stepwise-ablation control group. The maps showed incessantly changing beat-to-beat wave fronts and varying spatiotemporal behavior of driver activities. Reentries were not sustained (median, 2.6 rotations lasting 449±89 ms), meandered substantially but recurred repetitively in the same region. In total, 4720 drivers were identified in 103 ...

Driver Domains in Persistent Atrial Fibrillation

A dvances in hemato-oncology have led to the develop- ment of chimeric antigen receptor (CAR) T cells therapies that obtained marketing authorization in Europe to treat hematological diseases in 2018 following the same 2017 decisions by the FDA: Kymriah (tisagenlecleu- cel, tisa-cel, Novartis Laboratory) and Yescarta (axicabtagene ciloleucel, axi-cel, Gilead). The FDA indication for tisa-cel is as follows: children and young adults up to 25 years of age, with refractory B-cell acute lymphoblastic leukemia (ALL) or relapse after transplant or after the second relapse, and adults with aggressive large B-cell lymphomas, relapsed or refractory after the second or more line of systemic therapy. Indications for axi-cel include adults with relapsed/refractory aggressive large B-cell lymphomas after a second or greater line of systemic therapy. These authorizations followed the report of favorable results across noncomparative phase II pivotal clinical trials with limited follow-up, namely, ZUMA-1 for axi-cel 1 and the ELIANA 2 and JULIET 3 trials for tisa-cel. Such noncomparative designs for marketing authorization are consistent with increasing approvals based on limited evidence. 4 Therefore, we hypothesized that population and CAR-T-cells effects based on real-world data (RWD) could differ from those observed in such single-arm clinical trials. We thus aimed to compare the characteristics

Marie-Quitterie Picat

Papers

Driver Domains in Persistent Atrial Fibrillation

Real-world Experience of Approved Chimeric Antigen Receptor T-cell Therapies Compared to Clinical Trials Data